BACKGROUND AND AIM: Previous studies have identified Chuanxiong Renshen decoction as a promising anti-Alzheimer's disease (AD) agent, with its brain-penetrating components characterized via UHPLC-MS/MS. This study further elucidates the anti-neuroinflammatory mechanisms of Chuanxiong-Renshen medicine pair (CRM) in AD.
MATERIALS AND METHODS: 3 × Tg-AD mice were administered CRM for two months, and cognitive function was evaluated using novel object recognition (NOR) and Morris water maze (MWM) tests. Neuroinflammation and pathological markers were assessed via multiplex immunofluorescence (targeting Iba-1, CD86, P-Tau, and APP), hematoxylin-eosin (HE) staining, and network pharmacology. Serum metabolomics (UHPLC-MS/MS) and 16S rRNA sequencing were employed to analyze metabolic and gut microbiota alterations. In vitro, LPS-stimulated BV-2 microglia were treated with CRM-containing serum, followed by evaluation of CD86expression (flow cytometry), pro-inflammatory cytokines, and PKC-α/NF-κB pathway proteins. Pathway specificity was further validated using the PKC-α inhibitor Gö6976. + +
RESULTS: CRM significantly ameliorated cognitive deficits and reduced Iba-1, CD86, P-Tau, and APP expression in 3 × Tg-AD mice. Mechanistically, CRM suppressed PKC-α/NF-κB signaling, down-regulating iNOS, COX-2, and p-NF-κB p65 in microglia, with synergistic effects observed upon PKC-α inhibition. Additionally, CRM modulated gut microbiota composition, notably reducing Proteobacteria abundance, which correlated with hippocampal Iba-1 and APP levels. +
CONCLUSION: These findings demonstrate that CRM exerts neuroprotective effects in AD through dual mechanisms: inhibition of PKC-α/NF-κB-mediated neuroinflammation and restoration of gut microbiota homeostasis. Thus, CRM represents a promising multi-target therapeutic strategy for AD.
